Liver Diseases: Screening

(asked on 7th November 2023) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the letter of 7 March 2023 from the then Minister for Social Care to the Chief Executive of the British Liver Trust, whether it remains his policy that fibroscans will be in use at 100 community diagnostic centres by March 2025; how many fibroscans have been delivered to community diagnostic centres since March 2023; and whether he has made an assessment of the potential merits of setting a new target.


Answered by
Andrew Stephenson Portrait
Andrew Stephenson
Minister of State (Department of Health and Social Care)
This question was answered on 27th February 2024

There is currently no national target specifically relating to the availability of FibroScan equipment, or testing for liver fibrosis, through Community Diagnostic Centres (CDCs) in England by March 2025.

The CDC modality offer is based on the recommendations in the Sir Mike Richards Review, in which Fibroscans were included as a suitable optional additional test for use in CDCs. Decisions on what modalities are offered outside of the core requirements of CDCs will be based on local need and decisions.

I can confirm there are currently plans for 12 CDCs to offer FibroScan testing, of which seven are operational. A further five CDCs plan to offer this service by the end of March 2024.

However, the Government takes very seriously the importance of preventative action, and of identifying patients at risk of liver disease and diagnosing it earlier. It is a fast-growing cause of mortality and morbidity; and one we want to make progress in tackling.

The Government is working with the National Health Service to support earlier diagnosis of liver disease and identifying patients at risk. This includes plans agreed as part of the £2.3 billion diagnostics transformation programme, including upgrading laboratory digital capabilities to ensure that labs across the country have the capability required to offer Intelligent Liver Function Tests. This test is highly effective as a first line diagnostic test to identify patients at higher risk, who may benefit from a FibroScan, or enhanced Liver function test.

The Government is also working with the NHS to deliver and consider the result from the pilot of the community liver health check programme – which in its first year delivered over 17,000 FibroScans to individuals at particular risk of liver disease, through the use of 40 FibroScanners, 12 of which were located in mobile units, across 19 local areas. This is in addition to wider work on health prevention, including vaccination and alcohol awareness programmes.

The Government will continue to look at options to go further. Over the coming year, NHS England are due to pilot a new diagnostic pathway it has developed for liver disease, which will include Fibrosis scanning in CDCs – we look forward to seeing the results of that pilot.

Reticulating Splines